Abstract. Cervical cancer is one of the leading causes of cancer-related mortality worldwide. Previously, the upregulation of microRNA (miR)-10a has been identified in human cervical cancer. The present study firstly demonstrated that miR-10a was markedly upregulated in primary tumor tissues in patients with positive lymph node metastasis (LN + ) compared with negative (LN -) by quantitative polymerase chain reaction. miR-10a mimics markedly enhanced cervical cancer cell migration and invasion abilities, and accordingly the miR-10a inhibitor suppressed those functions. Furthermore, these data suggested that the phosphatase and tensin homologue (PTEN) was inhibited by miR-10a through an miR-10a binding site within the 3'-untranslated region of PTEN at the posttranscriptional level, and that miR-10a mimics promoted nuclear translocation of β-catenin. Therefore, it was concluded that the overexpression of miR-10a contributes to metastasis in cervical cancer by targeting PTEN. miR-10a may therefore be used clinically as a molecular marker for patients with cervical cancer lymph node metastasis.
Introduction
The presence of lymph node metastases is the main prognostic factor in early-stage cervical cancer patients. Although the International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical carcinoma does not take into account the lymphadenopathy (LN) status, it is the most significant prognostic factor for patients with stages IB or IIA of the disease. In addition, the 5-year survival rate for patients declines markedly from ~80-95% in patients without lymph node metastasis to ~50-65% in patients with lymph node metastases (1) . Radical hysterectomy and pelvic lymphadenectomy is the standard surgical treatment for early stage cervical cancer. However, in a clinical study by Selman et al (2) it was confirmed that 84% patients did not exhibit pathology following a lymph node biopsy. Numerous studies have focused on strategies for detecting lymph node metastasis; however, the accuracy of these approaches, such as MRI and PET-CT, was identified to be only 50% (3) . Therefore, the identification of sensitive, accurate and non-invasive molecular markers may facilitate the selection of patients with lymph node negative cervical cancer with an unfavorable prognosis for adjuvant treatment and allow the identification of targets for patient-tailored therapy.
MicroRNA (miR) has an essential role in malignant tumor development and progression (4, 5) . Previous studies have demonstrated that certain miRs control tumor cell invasion and metastasis. For example, miR-200c initiated metastasis mediated by the loss of cell-cell adhesion caused by E-cadherin repression, in a process commonly termed epithelial-to-mesenchymal transition (EMT) (6) . In addition, miR-26a enhanced the metastatic potential of lung cancer cells via the AKT pathway by targeting phosphatase and tensin homologue (PTEN) (7) . Furthermore, enforced expression of miR-148a suppressed gastric cancer cell invasion and metastasis through directly targeting ROCK1 (8) . The role of miR-10a in cancer metastasis has recently attracted notable attention. Microarray analysis data by Pereira et al (9) and Lee et al (10) demonstrated that miR-10a is upregulated in cervical cancer. It was also demonstrated that miR-10a triggered the metastatic properties of hepatocellular carcinoma by directly targeting EphA4 (11) . Furthermore, the expression of miR-10a was at least 10-fold higher in three gastric cancer cell lines compared with gastric mucosal cell lines, and was involved in the development of gastric cancer and lymph node metastasis (12) . In addition, circulating miR-10a was reported to be higher in the plasma of patients with non-small cell lung cancer compared with that in healthy volunteers (13) . By contrast, controversial results have emerged reporting miR-10a to be a tumor suppressor by controlling cell migration/invasion in esophageal squamous cell carcinoma (14) . However, the function of miR-10a in cervical cancer remains unknown and further study is warranted to elucidate this.
Therefore, the present study investigated the associated between the expression level of miR-10a and lymph node metastasis in cervical cancer, and further investigated the possible function of miR-10a in cervical cancer cell lines. The Cell transfection. The miR-10a gain and loss-of-function studies were performed using miR-10a mimics (100 nM) and its negative control (mimic nc; 100 nM) and the loss-of-function study were performed with miR-10a inhibitor (150 nM) and its negative control (inhibitor nc; 150 nM) in Hela and Siha cell lines (all obtained from Guangzhou RiboBio Co., Ltd., Guangzhou, China). For each cell line, there was a blank control without any transfection. The cells were transfected using Lipofectamine™ 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) in Opti-minimal essential medium (Gibco-BRL, Carlsbad, CA, USA), according to the manufacturer's instructions. The relative expression level of miR-10a in transfected cells was examined by quantitative polymerase chain reaction (qPCR).
MicroRNA
Dual-luciferase reporter assay. The region of human PTEN-3'UTR, generated by PCR amplification, was cloned into the pGL3 luciferase reporter plasmid. The primers selected were as follows: Forward: hsa-miR-10a 5'-CTCGAGGAAATAAAACCAAAGCACTC-3' and reverse: 5'-GGTACCGCCAGTCACCAGACTGTCCT-3' for hsa-miR-10a-R; and forward: 5'-TCTAGAAATGGC AATAGGACATTGTG-3' and reverse: 5'-TCTAGACCATCT TTATTAATCCTAATTG-3' for PTEN-3'UTR-wild type (wt).
For the reporter assay, 239 T cells were plated onto 24-well plates and transfected with 500 ng pGL3-miR-PTEN-wt using Lipofectamine 2000. Following transfection for 48 h, the cells were harvested and the Renilla and Firefly luciferase were assayed by the Dual Luciferase Reporter Assay system (GeneChem, Shanghai, China) according to the manufacturer's instructions. The tests were repeated in triplicate.
RNA extraction, reverse transcription and qPCR. Total RNA from the tissue samples and cells were isolated using TRIzol reagent (Ambion, Invitrogen Life Technologies). The relative expression levels of miR-10a were examined by the altered stem-loop RT-PCR with specific RT and PCR primers using U6 snRNA as a control. The primers for miR-10a were as follows: Forward: 5'-GCCGTACTC TGTAGATCCGAA-3' and reverse: 5'-CAGTGCAGGGTCCGAGGTAT-3'. The expression of PTEN mRNA was detected by qPCR using paired primers. The GAPDH gene was used as a control. The primers for PTEN mRNA were as follows: forward: 5'-A AGACCATA ACCCACCACAGC-3' and reverse: 5'-GAGCCCCAGCCTTCTCCAT-3'. qPCR was performed on a
Step One Plus Real-time PCR system (Applied Biosystems, Foster City, CA, USA) using SYBR Premix Ex Taq ™ (Takara Biotechnology, Dalian, China) according to the manufacturer's instructions. The 2 -ΔΔCt method, where ΔΔCT = (Ct target gene-CtU6)N + -(Ct target gene-CtU6)N 0 was used for analysis. Where N + represents the patients positive for lymph node metastasis and N 0 represents the patients negative for lymph node metastasis.
In vitro transwell invasion and migration assay. Transwell membranes (polycarbonic membrane; diameter, 6.5 mm; pore size, 8 µm; Corning Costar, Inc., Corning, NY, USA) coated with Matrigel (BD BioSciences, USA) were used to assay the cell invasion and migration in vitro. At 48 h post-transfection, the cells were resuspended into serum-free medium. The transfected cells (10x10 4 in 200 µl serum-free medium) were reseeded into the upper chamber, and 600 µl medium with 10% FBS was added to the lower chamber as a chemoattractant. Following 24 h incubation, non-invading cells on the upper surface of the membrane were removed with a cotton swab. The invasive cells, which penetrated to the lower surface, were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of cells invading the membrane was counted from five randomly selected visual fields with an inverted microscope (Olympus, Tokyo, Japan) at a magnification of x200. Data were obtained from three independent experiments.
Wound healing assay. The Hela and Siha cells were seeded onto 6-well plates. When the cell confluence reached ≥80% and above at ~48 h post-transfection, the scratch wounds were made by scraping the cell layer across each culture plate using the tip of 10 µl pipette. Then five fields were randomly selected from each scratch wound and visualized by microscopy. The experiments were performed in triplicate.
Immunocytochemistry. The Hela and Siha cells were seeded onto 13-mm glass coverslips on a 24-well plate. At 48 h following transfection with the non-specific control, miR-10a mimic (100 nM) cells were immunostained with anti-β-catenin antibody (Abnova, Taipei, Taiwan) according to the immunofluorescence staining instructions provided by the manufacturer. The labeled cells were observed with a A1Si confocal microscope (Nikon, Tokyo, Japan).
Western blotting. The Hela and Siha cells were harvested after 72 h following transfection with the miR-10a mimic, mimic nc, inhibitor or inhibitor nc. Equal quantities of the denatured protein sample were separated by SDS-PAGE and then transferred to polyvinylidene difluoride membranes (Wuhan Goodbio Technology Co., Ltd., Wuhan, China). The following primary antibodies were used: Anti-PTEN (dilution, 1:100; Abnova) and anti-β-actin (dilution, 1:400; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Following overnight incubation at 4˚C and washing, the membranes were probed with horseradish peroxidase-conjugated goat anti-rabbit antibody (Guge) at 1:5,000 dilution. The images were captured with the exposure machine (UVP OptiCam600; UVP Inc., Upland, CA, USA).
Statistical analysis.
The results were analyzed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Statistical analysis was performed using a Mann-Whitney test and one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression level of miR-10a is upregulated in cervical cancer tissues with pelvic lymph node metastasis.
To identify the miR-10a expression in the clinical samples, qPCR was performed and it was identified that following normalization to RNU6B expression levels, the expression level of miR-10a in cervical cancer tissues with LN + [mean ± standard deviation (SD): 0.000003448+0.00008553] was significantly higher than LN -(mean ± SD: 0.000001109+0.000002271; P=0.0053), as demonstrated in Fig. 1A . This data suggested that miR-10a may directly function in cervical cancer cell metastasis.
Upregulation of miR-10a expression promotes invasion and migration of cervical cancer cells.
As the results above demonstrated that the upregulation of miR-10a in cervical cancer is closely associated with cervical cancer metastasis, it was hypothesized that the overexpression of miR-10a in cervical 
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cancer cells exerted effects of cell invasion and metastasis. In gain-of-function and loss-of-function studies, Hela and Siha cells were separately transfected with mimic and mimic nc, inhibitor and inhibitor nc. Transfection with 100 nM of miR-10a mimics in Hela cells led to an ~1328-fold increase in the miR-10a expression detected 48 h post-transfection, as examined by qPCR (Fig. 1B) . It was identified that the overexpression of miR-10a induced Hela and Siha cell migration, while downregulated miR-10a could inhibit the migratory ability of Hela and Siha cells ( Fig. 2A and C) . Consistent with this finding, the matrigel invasion assay results demonstrated that miR-10a overexpression significantly enhanced the invasion capacity of Hela and Siha cells, while decrease of miR-10a could inhibit invasion in Hela and Siha cells, however, this was not statistically significant (Fig. 2B) . These observations demonstrated that miR-10a had an important role in promoting migration and the invasive potential of cervical cancer cells.
miR-10a targets PTEN.
The analysis conducted using publicly available programs, TargetScan (http://www.targetscan. org) and miRanda (http://www.microrna.org), indicated that PTEN is theoretically the target gene of miR-10a (Fig. 3A) . Next, a luciferase reporter assay was performed to verify that miR-10a directly targets PTEN. It was identified that co-transfection of pGL3-miR-10a and pGL3-PTEN-wt, 
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significantly decreased the luciferase activity in 239 T cells as compared with the control (Fig. 3B) .
Alteration of miR-10a expression changes PTEN protein but not mRNA expression levels. PTEN had been reported to be downregulated in cervical cancer and closely associated with lymph node metastasis. To further confirm that PTEN was the downstream target of miR-10a, upregulation and downregulation of miR-10a expression were conducted with subsequent detection of PTEN mRNA and protein changes. The increase in endogenous miR-10a levels significantly decreased PTEN protein expression as determined by western blot analysis (P<0.05; Fig. 3C ), while the mRNA expression of PTEN remained unchanged (data not shown).
miR-10a mimic promotes nuclear translocation of β-catenin.
Considering that PTEN was able to restrain β-catenin nuclear translocation and miR-10a inhibited PTEN expression, it was determined whether miR-10a may affect the β-catenin nuclear translocation activity. Notably, the immunofluorescence staining assays demonstrated that the overexpression of miR-10a resulted in marked nuclear accumulation of β-catenin in Hela and Siha cervical cancer cell lines, suggesting that miR-10a may contribute to the accumulation of β-catenin in the nuclei (Fig. 3D ).
Discussion
Lymph node status is one of the most important prognostic factors following cervical cancer diagnosis, which dominates the majority of clinical decisions regarding treatment (15, 16) . As the current imaging techniques are not reliable to diagnose lymph node status, pelvic +/-para-aortic lymphadenectomy remains the gold standard. These surgical procedures are, however, responsible for specific morbidity: Lymphocele and lymphedema. However, lymph node metastasis is rarely identified by CT or MRI when they are <1 cm. Therefore, effective molecular markers for detecting lymph node metastasis are urgently required (17, 18) . Previously, a number of miRNAs were identified to be lymph node metastasis biomarkers, including miRNA-10b and miRNA-373, which are used for detecting lymph node metastasis of breast cancer (19) . Furthermore, miR-21, miR-212 and miR-195 were found to be promising novel biomarkers for lymph node metastasis in gastric cancer (20, 21) , and it appears miR-20a may be a potential biomarker for detecting the lymph node status of cervical cancer patients (22) . The miR-10 family containing five miRNA genes, including miR-10a, miR-10b, miR-196a-1, miR-196a-2 and miR-196b, has attracted notable attention due to its conservation and the position of the miR-10 genes within the Hox clusters of developmental regulators (23) . For miR-10a, it interacts with the 5' untranslated region of mRNAs encoding RPs (ribosomal proteins) to enhance their translation. Accordingly, RPs are found to be deregulated in cancer (24) . Furthermore, miR-10a was found overexpressed in glioblastoma, hepatocellular carcinomas, colon cancer and acute myeloid leukemia with NPM1 mutations (25) (26) (27) (28) . In the present study, it was identified that miR-10a in primary tumor tissue was markedly upregulated in N + patient samples. Next, the function and possible mechanisms of miR-10a in regulating certain biological properties of Hela and Siha cervical cancer cells was investigated. However, through MTT and flow cytometry, it was verified that miR-10a had no effect on the cell proliferation and apoptosis in 72 h (data not shown). The data also suggested that a miR-10a mimic triggered the migration and invasion capacities of cervical cancer cells by negatively regulating tumor suppressor PTEN at the transcriptional level via binding to non-coding regions of PTEN. PTEN is a tumor suppressor that negatively regulates (mTOR)/PI3K/Akt pathways. PTEN is one of the most mutated and deleted tumor suppressors in human cancer and has an important role in tumor metastasis (29) (30) (31) (32) . Loss of PTEN is associated with lymph node metastasis of cervical cancer (33, 34) , sentinel lymph node micro-metastasis in breast cancer (35) and cervical lymph node metastasis in salivary gland cancer (36) . The present study found that an miR-10a mimic was able to inhibit PTEN at the transcriptional level. The function of PTEN is involved in the suppression of nuclear-catenin accumulation (37, 38) . The results demonstrated that the miR-10a mimic was able to trigger β-catenin nuclear translocation. In cancer cells, β-catenin within the nucleus generates a positive and reinforcing feedback loop, resulting in the nuclear accumulation of β-catenin (39) . A strong correlation has been identified between β-catenin nuclear translocation, tumor metastasis and poor prognosis (40) (41) (42) . In cervical cancer, β-catenin nuclear translocation has been noted for its function in lymph node metastasis, growth, invasion and angiogenesis (41, 43) . Stabilization and nuclear localization of β-catenin, which induces the expression of Wnt target genes and subsequently triggers EMT, may be associated with the induction of metastasis (44) . The present study suggests that the mechanisms of miR-10a promoting the invasion and migration ability of Hela and Siha cells, may be that miR-10a inhibits PTEN protein expression and then promotes β-catenin accumulation in the nucleus. To the best of our knowledge, this mechanism has not been reported prior to this study and requires further investigation.
In conclusion, it was observed that miR-10a is overexpressed in cervical tumor tissues with lymph node metastasis, and miR-10a may significantly enhance the migration and invasion capacities of cervical cancer cells by inhibiting PTEN at the transcriptional level. To the best of our knowledge, these data have not been documented in previous studies. The present data suggests that miR-10a may be useful as a molecular marker for detecting patients with lymph node metastasis of cervical cancer. These findings warrant further studies with a large cohort of patients to validate and develop the tissue biomarker as a critical tool for cervical cancer care.
